Neuromodulation in Parkinson’s disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach-Reference-Cited by-同舟云学术

Neuromodulation in Parkinson’s disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach

Published:2023-06-15 Issue:4 Volume:31 Page:1605-1627
ISSN:0925-4692
Container-title:Inflammopharmacology
language:en
Short-container-title:Inflammopharmacol

Author:

Alam Md Reyaz,Singh Shamsher^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Immunology

Link

https://link.springer.com/content/pdf/10.1007/s10787-023-01259-0.pdf

Reference204 articles.

1. Abascal K, Yarnell E (2004) Alzheimer’s disease: part 2—a botanical treatment plan. Altern Complement Ther 10:67–72

2. Abbott A (2010) Levodopa: the story so far. Nature 466:S6–S7

3. Agid Y, Javoy-Agid F (1985) Peptides and Parkinson’s disease. Trends Neurosci 8:30–35

4. Aguado T, Palazuelos J, Monory K, Stella N, Cravatt B, Lutz B, Marsicano G, Kokaia Z, Guzmán M, Galve-Roperh I (2006) The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J Neurosci 26:1551–1561

5. Ajmone-Cat MA, Bernardo A, Greco A, Minghetti L (2010) Non-steroidal anti-inflammatory drugs and brain inflammation: effects on microglial functions. Pharmaceuticals 3:1949–1965

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative susceptibility mapping of multiple system atrophy and Parkinson's disease correlates with neurotransmitter reference maps;Neurobiology of Disease;2024-08

2. The establishment and application of animal models for neurodegenerative diseases;Chinese Science Bulletin;2023-10-01